Skip to main content Skip to footer
American Family Children's Hospital
SHARE TEXT
 
Glenn Liu, MD close
EW7oV-dVusU
Glenn Liu, MD
 

New Patients

Need help selecting a primary care doctor? Contact the Welcome Center for personal assistance.

For Referring Physicians

How to refer a patient

Glenn Liu, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Liu joined the faculty as an Assistant Professor of Medicine at the University of Wisconsin in 2003, where he currently specializes in genitourinary oncology and experimental therapeutics. Previously, Dr. Liu did his undergraduate training at Dartmouth College, where he majored in biochemical engineering. From there, he received his Master's Degree at Boston University before obtaining his MD at Jefferson Medical College. Dr. Liu completed his internal medicine and oncology training at the University of Wisconsin Hospital and Clinics, with additional training in genitourinary oncology as part of a K12 grant at the University of Wisconsin Carbone Cancer Center.

Specialties

Clinics

UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map
UW Carbone Cancer Center
(608) 263-4757 | (800) 323-8942 | Map

Hospital Affiliation(s)

University Hospital
Veterans Hospital - Wm. S. Middleton Memorial

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Medical Oncology
Fellowship Oncology, University of Wisconsin Hospital and Clinics, Madison, WI
Residency University of Wisconsin Hospital and Clinics, Madison, WI
Internship University of Wisconsin Hospital and Clinics, Madison, WI
Medical School Thomas Jefferson Medical College, Philadelphia, PA

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.
Research

Dr. Liu specializes in the treatment of all genitourinary cancers and is a recognized clinical researcher as evident by his service on the Eastern Cooperative Oncology Group (ECOG) Genitourinary Oncology Core Committee as the Genitourinary (GU) Liaison for the ECOG Developmental Therapeutics Committee, for which he is also a member. He currently serves as the disease group leader for the GU Oncology Disease Group, a NCI-designated Phase II Consortium, and thus is highly active in local, regional, and national trials in all stages of development. Dr. Liu is also a member of the experimental therapeutics (Phase I) program at the UW Carbone Cancer Center, and thus is involved in early drug development.


PubMed Articles
Harshman LC Chen YH Liu G Carducci MA Jarrard D Dreicer R Hahn N Garcia JA Hussain M Shevrin D Eisenberger M Kohli M Plimack ER Cooney M Vogelzang NJ Picus J Dipaola R Sweeney CJ ECOG-ACRIN 3805 Investigators. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol . 2018 Feb 1;36(4):376-382
[PubMed ID: 29261442]
Kyriakopoulos CE Chen YH Carducci MA Liu G Jarrard DF Hahn NM Shevrin DH Dreicer R Hussain M Eisenberger M Kohli M Plimack ER Vogelzang NJ Picus J Cooney MM Garcia JA DiPaola RS Sweeney CJ Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol . 2018 Jan 31;:JCO2017753657
[PubMed ID: 29384722]
Pili R Jegede O Carducci MA Manola J Groteluschen DL Appleman LL Liu G Shanks JC Dakhil SR Dutcher J DiPaola RS A Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients With Metastatic Renal Cell Carcinoma (ECOG-ACRIN [E4805]). Clin Genitourin Cancer . 2017 Dec;15(6):642-651.e1
[PubMed ID: 28545998]
Jared JR Mably MS Makielski R Reed MP Fallon MJ Liu G Mulkerin D Callander NS Utilization and evaluation of noncore chemotherapy regimens within an academic medical center. J Oncol Pharm Pract . 2017 Oct;23(7):518-524
[PubMed ID: 27388159]
Harmon SA Perk T Lin C Eickhoff J Choyke PL Dahut WL Apolo AB Humm JL Larson SM Morris MJ Liu G Jeraj R Quantitative Assessment of Early [<sup>18</sup>F]Sodium Fluoride Positron Emission Tomography/Computed Tomography Response to Treatment in Men With Metastatic Prostate Cancer to Bone. J Clin Oncol . 2017 Aug 20;35(24):2829-2837
[PubMed ID: 28654366]
Kyriakopoulos CE Braden AM Kolesar JM Eickhoff JC Bailey HH Heideman J Liu G Wisinski KB A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors. Invest New Drugs . 2017 Jun;35(3):290-297
[PubMed ID: 28004284]
Ehlerding EB England CG Majewski RL Valdovinos HF Jiang D Liu G McNeel DG Nickles RJ Cai W ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer. Mol Pharm . 2017 May 1;14(5):1782-1789
[PubMed ID: 28388076]
England CG Ehlerding EB Hernandez R Rekoske BT Graves SA Sun H Liu G McNeel DG Barnhart TE Cai W Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab. J Nucl Med . 2017 Jan;58(1):162-168
[PubMed ID: 27493273]
Engle JA Traynor AM Campbell TC Wisinski KB LoConte N Liu G Wilding G Kolesar JM Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center. J Oncol Pharm Pract . 2017 Jan 1;:1078155217704989
[PubMed ID: 28457192]
Scarpelli M Bruce JY Carmichael L Eickhoff J Kolesar J Perlman S Jeraj R Liu G <sup>18</sup>F-FLT PET/CT imaging in patients with advanced solid malignancies treated with axitinib on an intermittent dosing regimen. Cancer Chemother Pharmacol . 2016 Dec;78(6):1245-1252
[PubMed ID: 27817059]
Smith MR Antonarakis ES Ryan CJ Berry WR Shore ND Liu G Alumkal JJ Higano CS Chow Maneval E Bandekar R de Boer CJ Yu MK Rathkopf DE Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. Eur Urol . 2016 Dec;70(6):963-970
[PubMed ID: 27160947]
Lin C Bradshaw T Perk T Harmon S Eickhoff J Jallow N Choyke PL Dahut WL Larson S Humm JL Perlman S Apolo AB Morris MJ Liu G Jeraj R Repeatability of Quantitative 18F-NaF PET: A Multicenter Study. J Nucl Med . 2016 Dec;57(12):1872-1879
[PubMed ID: 27445292]
Kyriakopoulos CE Liu G Chemohormonal Therapy for Hormone-Sensitive Prostate Cancer: A Review. Cancer J . 2016 Sep Oct;22(5):322-325
[PubMed ID: 27749324]
Wisinski KB Tevaarwerk AJ Burkard ME Rampurwala M Eickhoff J Bell MC Kolesar JM Flynn C Liu G Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer. Clin Cancer Res . 2016 Jun 1;22(11):2659-67
[PubMed ID: 27026198]
Scher HI Morris MJ Stadler WM Higano C Basch E Fizazi K Antonarakis ES Beer TM Carducci MA Chi KN Corn PG de Bono JS Dreicer R George DJ Heath EI Hussain M Kelly WK Liu G Logothetis C Nanus D Stein MN Rathkopf DE Slovin SF Ryan CJ Sartor O Small EJ Smith MR Sternberg CN Taplin ME Wilding G Nelson PS Schwartz LH Halabi S Kantoff PW Armstrong AJ Prostate Cancer Clinical Trials Working Group 3. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol . 2016 Apr 20;34(12):1402-18
[PubMed ID: 26903579]
Kyriakopoulos CE Heath EI Eickhoff JC Kolesar J Yayehyirad M Moll T Wilding G Liu G A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer. Invest New Drugs . 2016 Apr;34(2):225-30
[PubMed ID: 26924129]
Deming DA Cavalcante LL Lubner SJ Mulkerin DL LoConte NK Eickhoff JC Kolesar JM Fioravanti S Greten TF Compton K Doyle AG Wilding G Duffy A Liu G A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. Invest New Drugs . 2016 Apr;34(2):168-75
[PubMed ID: 26666244]
Bruce JY LoRusso PM Goncalves PH Heath EI Sadowski E Shalinsky DR Zhang Y Traynor AM Breazna A Ricart AD Tortorici M Liu G A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors. Cancer Chemother Pharmacol . 2016 Mar;77(3):527-38
[PubMed ID: 26791870]
Stein MN Hussain M Stadler WM Liu G Tereshchenko IV Goodin S Jeyamohan C Kaufman HL Mehnert J DiPaola RS A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer. Clin Genitourin Cancer . 2016 Feb;14(1):22-7
[PubMed ID: 26476589]
Thakur MK Heilbrun LK Sheng S Stein M Liu G Antonarakis ES Vaishampayan U Dzinic SH Li X Freeman S Smith D Heath EI A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study. Invest New Drugs . 2016 Feb;34(1):112-8
[PubMed ID: 26581400]